Lenalidomide in patients with POEMS syndrome: A systematic review and pooled analysis

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2018-2023

  Zagouri, Flora ^a   Kastritis, Efstathios ^a   Gavriatopoulou, Maria ^a   Sergentanis, Theodoros N ^b   Psaltopoulou, Theodora ^b   Terpos, Evangelos ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Lenalidomide; POEMS; pooled analysis; systematic review; treatment

Indexed keywords

LENALIDOMIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NEUROPATHY; POEMS SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; AGED; ANALOGS AND DERIVATIVES; META ANALYSIS; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; POEMS SYNDROME; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84906070158     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.869329     Document Type: Article

References (46)

1. Dispenzieri A. How I treat POEMS syndrome. Blood 2012; 119: 5650-5658.
2. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 591-601.
3. Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996; 347: 702.
4. Feinberg L, Temple D, de Marchena E, et al. Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature. Crit Rev Oncogenesis 1999; 10: 293-302.
5. H ashiguchi T, A rimura K, M atsumuro K, et al. Highly concentrated vascular endothelial growth factor inplatelets in Crow-Fukase syndrome. Muscle Nerve 2000; 23: 1051-1056.
6. K uwabara S, M isawa S, K anai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006; 66: 105-107.
7. Authier FJ, Belec L, Levy Y, et al. All-trans-retinoic acid in POEMS syndrome. Therapeutic effect associated with decreased circulating levels of proinflammatory cytokines. Arthritis Rheum 1996; 39: 1423-1426.
8. L i J, Zhang W, J iao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011; 117: 6445-6449.
9. Davis L, Drachman D. Myeloma neuropathy. Arch Neurol 1972; 27: 507-511.
10. Philips ED, el-Mahdi AM, Humphrey RL, et al. The effect of the radiation treatment on the polyneuropathy of multiple myeloma. J Can Assoc Radiol 1972; 23: 103-106.
11. Broussolle E, Vighetto A, Bancel B, et al. P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma. Clin Neurol Neurosurg 1991; 93: 165-170.
12. Cabezas-Agricola JM, Lado-Abeal JJ, Otero-Anton E, et al. Hypoparathyroidism in POEMS syndrome. Lancet 1996; 347: 701-702.
13. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104: 3400-3407.
14. I noue D, K ato A, T abata S, et al. Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide. Intern Med 2010; 49: 461-466.
15. Sinisalo M, Hietaharju A, Sauranen J, et al. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004; 76: 66-68.
16. Kim SY, Lee SA, Ryoo HM, et al. Thalidomide for POEMS syndrome. Ann Hematol 2006; 85: 545-546.
17. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005; 106: 1135.
18. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006; 107: 4972-4973.
19. Samaras P, Bauer S, Stenner-Liewen F, et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007; 92: 1438-1439.
20. Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008; 19: 595.
21. Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman's disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009; 2: 19.
22. Sobas MA, Alonso Vence N, Diaz Arias J, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome (MCD-POEMS variant). Ann Hematol 2010; 89: 217-219.
23. Tang X, Shi X, Sun A, et al. Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009; 83: 609-610.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.
25. D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 2012; 120: 56-62.
26. Furuta N, Tashiro Y, Ikeda M, et al. [ A case of POEMS syndrome associated with Waldenstr o m'smacroglobulinemia and treated with lenalidomide]. Rinsho Shinkeigaku 2012; 52: 186-189.
27. Matsuura S, Ogusa E, Taguchi J, et al. [POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy]. Rinsho Ketsueki 2012 53 2025-2028.
28. Suyani E, Yaǧci M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol 2011; 126: 199-201.
29. Royer B, Merlusca L, Abraham J, et al. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013; 88: 207-212.
30. Adam Z, Pour L, Krejči M, et al. [The effect of lenalidomide on rare blood disorders:Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. Vnitr Lek 2012; 58: 856-866.
31. Vannata B, Laurenti L, Chiusolo P, et al. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. Am J Hematol 2012; 87: 641-642.
32. Briani C, Manara R, Lessi F, et al. Pachymeningeal involvement in POEMS syndrome:dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol 2012; 87: 539-541.
33. Tomas JF, Giraldo P, Lecumberri R, et al. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica 2012; 97: 320-322.
34. Sethi S, Tageja N, Arabi H, et al. Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction. South Med J 2009; 102: 1092-1093.
35. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110: 1075-1076.
36. Nozza A, Terenghi F, Mazza R, et al. Efficacy of lenalidomide in patients with POEMS syndrome: a pilot study. Haematologica 2011; 96(Suppl. 3): Abstract C010.
37. Kuehne R, Goede J, Benz R, et al. Immune modulatory drugs in POEMS syndrome. Onkologie 2008; 31(Suppl. 4): Abstract P538.
38. Patel T, M oreno-Aspitia A. A lternative treatment for POEMS syndrome: a Lazarus response to lenalidomide. Blood 2008; 112(Suppl. 1): Abstract 5205.
39. Ramirez G, Campos A, Rosell A, et al. Patient suffering from POEMS syndrome treated with lenalidomide plus dexamethasone. Haematologica 2009; 94(Suppl. 2): Abstract 1631.
40. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
41. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
42. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
43. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010; 116: 3807-3814.
44. Dupont SA, Dispenzieri A, Mauermann ML, et al. Cerebral infarction in POEMS syndrome:incidence, risk factors, and imaging characteristics. Neurology 2009; 73: 1308-1312.
45. Weber D, Rankin K, G avino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 1: 16-19.
46. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.